Prospektive Versorgungsforschungsstudie zur Therapie mit Immunglobulinen (SIGNS)

[1]  R. Gold,et al.  Einsatz intravenöser Immunglobuline in der Neurologie , 2010, Der Nervenarzt.

[2]  H. Bueno,et al.  The role of cardiac registries in evidence-based medicine. , 2010, European heart journal.

[3]  S. Jacob,et al.  Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies , 2009, Current neuropharmacology.

[4]  E. Neugebauer,et al.  Die Erfassung von Lebensqualität in der Versorgungsforschung - konzeptuelle, methodische und strukturelle Voraussetzungen. , 2009 .

[5]  J. Jakobsen,et al.  Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial , 2009, European journal of neurology.

[6]  W. Köbberling,et al.  Zu Viviane Knerr et al. Die ESID-Online-Datenbank für primäre Immundefekte , 2008, Medizinische Klinik.

[7]  B. Grimbacher,et al.  [The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe]. , 2008, Medizinische Klinik.

[8]  N. Gilhus,et al.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases , 2008, European journal of neurology.

[9]  Shigeaki Nonoyama,et al.  Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. , 2007, The Journal of allergy and clinical immunology.

[10]  M. Bullinger,et al.  [Methodological challenges and potentials of health-related quality of life evaluation in children with chronic health conditions under medical health care]. , 2007, Medizinische Klinik.

[11]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[12]  N. Leidy,et al.  Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  J S Alpert,et al.  Are data from clinical registries of any value? , 2000, European heart journal.

[14]  L. Hammarström,et al.  Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs , 1995, The Lancet.

[15]  M. Bullinger,et al.  Generic Health-Related Quality-of-Life Assessment in Children and Adolescents , 2012, PharmacoEconomics.

[16]  M. Koller,et al.  [Assessment of quality of life in health services research - conceptual, methodological and structural prerequisites]. , 2009, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[17]  L. Notarangelo,et al.  Primary immunodeficiency diseases , 2008 .